ActivX Biosciences

ActivX Biosciences was an emerging biopharmaceutical company with a focus on hematology, oncology, metabolic, and inflammatory diseases. Established in 2000, the company was a wholly owned subsidiary of Kyorin Pharmaceutical, LTD (Tokyo, JPN: 4569.T). Its core technology allowed for the identification and development of highly selective drugs, thereby lowering development risk. ActivX Biosciences aimed to discover and develop highly selective, best-in-class, small molecule drugs for major unmet medical needs, particularly in the protein kinase and protease families. The company's innovative approach involved identifying target and off-target activities of drug candidates. While specific information regarding the last investment and investors is not available, ActivX Biosciences was headquartered in the United States. Overall, ActivX Biosciences' focus on leveraging unique technology to develop highly selective drugs for critical medical needs in multiple disease areas represented a promising opportunity for potential investors in the biotechnology industry.